专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016175566A1 MEDIUM COMPOSITION FOR PREPARING BOTULINUM TOXIN 审中-公开
标题翻译：用于制备BOTULINUM TOXIN的中间组合物
公开(公告)号：WO2016175566A1
公开(公告)日：2016-11-03
申请号：PCT/KR2016/004431
申请日：2016-04-28
申请人： DAEWOONG CO., LTD.
发明人： KIM, Kyoung-Yun , SUL, Hye-Young , MIN, Kyoung-Min
IPC分类号： C12N5/00 , C07K14/33
CPC分类号： A61K39/385 , A61K39/39 , C07K14/33 , C12N1/20
摘要： The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises a casein hydrolysate and at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones, casein hydrolysates and minerals, is used for culture of Clostridium botulinum , the growth rate of the bacterium in the medium is higher than that in each of the medium that is in current use and the medium comprising plant-derived peptones alone. In addition, when the medium of the present invention is used, a high concentration of botulinum toxin can be produced by culturing the bacterium in a safe manner.
摘要翻译：本发明涉及用于生产肉毒杆菌毒素的培养基组合物，更具体地说，涉及用于培养梭菌属的培养基组合物。能够产生肉毒杆菌毒素。本发明的培养基组合物包含酪蛋白水解物和至少一种选自花生豌豆水解产物，棉籽水解产物和小麦谷蛋白水解产物的植物来源的蛋白胨。当将含有植物来源的胨，酪蛋白水解物和矿物质的本发明的培养基用于肉毒杆菌的培养时，培养基中细菌的生长速率高于培养基中培养的培养基目前的用途和包含单独植物来源的胨的培养基。此外，当使用本发明的培养基时，可以通过以安全的方式培养细菌来产生高浓度的肉毒杆菌毒素。

2. 发明申请

WO2010041889A3 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE 审中-公开
标题翻译：用于预防或治疗慢性阻塞性肺病的药物组合物
公开(公告)号：WO2010041889A3
公开(公告)日：2010-08-19
申请号：PCT/KR2009005770
申请日：2009-10-09
申请人： DAEWOONG CO LTD , YANG SUN MEE , LIM KWON JO , PARK HYUN JIN , KIM IL HWAN , LEE SANG HO , LEE JONG WOOK
发明人： YANG SUN MEE , LIM KWON JO , PARK HYUN JIN , KIM IL HWAN , LEE SANG HO , LEE JONG WOOK
IPC分类号： A61K38/18
CPC分类号： A61K38/1808
摘要： Provided is a pharmaceutical composition for preventing or treating mucus hypersecretion in airways or chronic obstructive pulmonary diseases (COPDs), the pharmaceutical composition including an epidermal growth factor (EGF) and a pharmaceutically acceptable carrier. In addition, a combined preparation capable of respectively administering the pharmaceutical composition and chemotherapeutics is provided.
摘要翻译：本发明提供用于预防或治疗呼吸道或慢性阻塞性肺病（COPD）中的粘液高分泌的药物组合物，所述药物组合物包含表皮生长因子（EGF）和药学上可接受的载体。另外，提供了能够分别施用药物组合物和化学治疗剂的组合制剂。

3. 发明申请

WO2007089051A1 COMPOSITION FOR TREATING CANCER COMPRISING OLIGONUCLEOTIDE AND NON-TOXIC LPS 审中-公开
标题翻译：用于治疗包含寡核苷酸和非毒性LPS的癌症的组合物
公开(公告)号：WO2007089051A1
公开(公告)日：2007-08-09
申请号：PCT/KR2006/000360
申请日：2006-02-01
申请人： EYEGENE INC. , DAEWOONG CO., LTD. , AHN, Bo-young , CHO, Yang-je , YOO, Won-il , LEE, Na-gyong , KIM, Doo-sik
发明人： AHN, Bo-young , CHO, Yang-je , YOO, Won-il , LEE, Na-gyong , KIM, Doo-sik
IPC分类号： A61K31/7088 , A61K31/739 , A61P35/00
CPC分类号： A61K31/7088 , A61K31/739 , Y02A50/473 , A61K2300/00
摘要： Disclosed is a composition for treating cancer including oligodeoxynucleotides and LPS-derived non-toxic lipopolysaccharides as effective components.
摘要翻译：公开了用于治疗癌症的组合物，包括寡脱氧核苷酸和LPS衍生的无毒性脂多糖作为有效成分。

4. 发明申请

WO2007032631A1 MARKERS FOR DIAGNOSIS OF CANCER AND ITS USE 审中-公开
标题翻译：癌症诊断标志及其使用
公开(公告)号：WO2007032631A1
公开(公告)日：2007-03-22
申请号：PCT/KR2006/003620
申请日：2006-09-12
申请人： DAEWOONG CO., LTD. , SHIN, InKyung , PARK, Hyun jin , CHOI, Joo young , HYUN, Hyae Jung , SHIN, Kyeong-Sun , PARK, Seung kook
发明人： SHIN, InKyung , PARK, Hyun jin , CHOI, Joo young , HYUN, Hyae Jung , SHIN, Kyeong-Sun , PARK, Seung kook
IPC分类号： C12N15/28 , G01N33/574 , C12Q1/68 , A61B5/00
CPC分类号： C12Q1/6886 , C07K14/4748 , C12N15/113 , C12N2310/14 , C12Q2600/158 , G01N33/57415 , G01N33/57419 , G01N33/57488
摘要： Disclosed herein are diagnostic markers CTHRCl, CANP and KIAA0101, which are overexpressed specifically in breast or colorectal cancer. A method for diagnosing the cancer by- detecting the markers, and a method for preventing or treating by inhibiting the expression and activity of the markers are also disclosed.
摘要翻译：本文公开了诊断标记物CTHRCl，CANP和KIAA0101，其特异性地在乳腺癌或结肠直肠癌中过表达。还公开了通过检测标记物来诊断癌症的方法，以及通过抑制标记物的表达和活性来预防或治疗的方法。

5. 发明申请

WO2022124525A1 니클로사마이드를 포함하는 근육내 및/또는 피하 투여용 약학적 조성물 审中-公开
公开(公告)号：WO2022124525A1
公开(公告)日：2022-06-16
申请号：PCT/KR2021/011292
申请日：2021-08-24
申请人： 주식회사 대웅제약 DAEWOONG PHARMACEUTICAL CO., LTD. [KR]/[KR] , 주식회사 대웅 DAEWOONG CO., LTD. [KR]/[KR] , 주식회사 대웅테라퓨틱스 DAEWOONG THERAPEUTICS [KR]/[KR]
发明人： 김태헌 KIM, Taeheon , 김유경 KIM, Yukyung , 박민영 PARK, Min Young , 이아름 LEE, Areum , 한주미 HAN, Jumi , 박현진 PARK, Hyunjin , 박상한 PARK, Sanghan , 강복기 KANG, Bokki , 김동환 KIM, Donghwan , 이민석 LEE, Minsuk
IPC分类号： A61K31/167 , A61K9/00 , A61K9/19 , A61K9/10 , A61K47/38 , A61P31/12 , A61P31/14
摘要： 본 발명은, 니클로사마이드 또는 이의 약학적으로 허용가능한 염, 이의 수화물 또는 이의 용매화물을 포함하는 니클로사마이드의 근육내 및/또는 피하 투여용 약학적 조성물에 관한 것으로, 높은 혈중 농도를 장시간 유지할 수 있는 효과를 나타낼 수 있으며, 바이러스 관련 질환의 예방 또는 치료에 효과적으로 사용될 수 있다.

6. 发明申请

WO2018135722A1 STABLE LIQUID COMPOSITION COMPRISING BOTULINUM TOXIN 审中-公开
公开(公告)号：WO2018135722A1
公开(公告)日：2018-07-26
申请号：PCT/KR2017/011438
申请日：2017-10-17
申请人： DAEWOONG CO., LTD.
发明人： YIM, Hyeona , KIM, Cheong-Sei
IPC分类号： A61K9/08 , A61K9/00 , A61K38/48 , A61K47/18 , A61K47/38 , A61K47/26 , A61K47/12
摘要： The present disclosure relates to a stable liquid composition comprising a botulinum toxin as an active ingredient which is ready-to-use without the need for a reconstitution process, and particularly, to a liquid composition capable of preventing the botulinum toxin from aggregating even when the botulinum toxin is contained at a low concentration to thereby exhibit high stability, and efficiently preventing adsorption, etc., to a container, to constantly maintain an activity of the botulinum toxin for each batch or for each liquid vial. Specifically, the present disclosure relates to the liquid composition comprising (i) a botulinum toxin as an active ingredient, (ii) L-alanine or methyl cellulose, (iii) a non-ionic surfactant, and (iv) a buffer, and optionally, an isotonic agent. The liquid composition of the botulinum toxin according to the present disclosure is which is ready-to-use without performing a reconstitution process, and thus, it is possible to improve user's convenience, and reduce a deviation of botulinum toxin activity, etc., due to dilution errors in the reconstitution process, etc. Further, the liquid composition according to the present disclosure efficiently prevents the botulinum toxin from aggregating even at a low botulinum toxin concentration to thereby have extremely excellent storage stability, and efficiently prevents adsorption of the botulinum toxin to a container, thereby constantly maintaining an activity of the botulinum toxin for each batch or for each liquid vial.

7. 发明申请

WO2016175565A1 MEDIUM COMPOSITION FOR PREPARING BOTULINUM TOXIN 审中-公开
标题翻译：用于制备BOTULINUM TOXIN的中间组合物
公开(公告)号：WO2016175565A1
公开(公告)日：2016-11-03
申请号：PCT/KR2016/004430
申请日：2016-04-28
申请人： DAEWOONG CO., LTD.
发明人： KIM, Kyoung-Yun , SUL, Hye-Young , MIN, Kyoung-Min
IPC分类号： C12N5/00 , C07K14/33 , C12R1/145
CPC分类号： C12N9/52 , C07K14/33 , C12N1/20 , C12N5/0025 , C12N2500/76 , C12Y304/24069
摘要： The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones and minerals, is used for culture of Clostridium botulinum , the growth rate of the bacterium in the medium is about 1.5-2 times higher than that in the medium that is in current use. In addition, when botulinum toxin is produced by culturing the bacterium in the medium, infection with transmissible spongiform encephalopathy (TSE) or the like can be prevented by blocking introduction of animal-derived components.
摘要翻译：本发明涉及用于生产肉毒杆菌毒素的培养基组合物，更具体地说，涉及用于培养梭菌属的培养基组合物。能够产生肉毒杆菌毒素。本发明的培养基组合物包含至少一种选自花生豌豆水解物，棉籽粒子水解物和小麦谷蛋白水解物的植物来源的蛋白胨。当将含有植物来源的胨和矿物质的本发明的培养基用于肉毒杆菌的培养时，培养基中细菌的生长速度比培养基中培养基的生长速度高约1.5-2倍目前使用。此外，通过在培养基中培养细菌产生肉毒杆菌毒素时，可以通过阻止动物来源成分的引入来防止传染性海绵状脑病（TSE）等的感染。

8. 发明申请

WO2015016462A1 METHOD FOR PRODUCTION OF BOTULINUM TOXIN 审中-公开
标题翻译：生产丁香毒素的方法
公开(公告)号：WO2015016462A1
公开(公告)日：2015-02-05
申请号：PCT/KR2014/004003
申请日：2014-05-07
申请人： DAEWOONG CO., LTD.
发明人： KIM, Chung Sei , SONG, Kwan Young , MIN, Kyoung Min , AN, Yeong Duk
IPC分类号： C07K1/36 , C07K1/30 , C07K1/18
CPC分类号： C12N9/52 , C07K14/33 , C12Y304/24069
摘要： The present invention relates to a method for production of a botulinum toxin, and more particularly to a method for preparation of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography. The use of the method of the invention toxin makes it possible to produce a high-purity botulinum toxin by a simple process, suggesting that the method is very economical and efficient. The botulinum toxin produced by the method of the invention has high purity compared to botulinum toxins produced by conventional methods, and thus has an increased ability to act in a local area. Thus, the systemic circulation of the botulinum toxin, which can result in side effects, is reduced to increase the safety. Accordingly, the botulinum toxin of the invention can be used for various purposes, including treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy.
摘要翻译：本发明涉及肉毒杆菌毒素的制备方法，更具体地涉及一种制备肉毒杆菌毒素的方法，所述方法包括以下步骤：（a）用酸处理产生肉毒杆菌毒素菌株的培养物以沉淀肉毒杆菌毒素（b）向沉淀的肉毒杆菌毒素中加入缓冲液，然后用蛋白酶抑制剂和核酸酶处理，从而提取肉毒杆菌毒素; （c）用酸处理提取的肉毒杆菌毒素以沉淀肉毒杆菌毒素并将沉淀溶解在缓冲液中; 和（d）通过阴离子交换色谱法纯化肉毒杆菌毒素。使用本发明毒素的方法使得可以通过简单的方法生产高纯度肉毒杆菌毒素，这表明该方法非常经济和有效。通过本发明的方法生产的肉毒毒素与通过常规方法生产的肉毒杆菌毒素相比具有高纯度，因此具有增强的局部作用能力。因此，可能导致副作用的肉毒杆菌毒素的全身循环被减少以增加安全性。因此，本发明的肉毒杆菌毒素可以用于各种目的，包括治疗神经肌肉疾病，去除皱纹，以及治疗痉挛性偏瘫和脑瘫。

9. 发明申请

WO2010027217A3 COMPOSITION FOR PREVENTING OR TREATING ALOPECIA CAUSED BY A CHEMOTHERAPEUTIC AGENT 审中-公开
公开(公告)号：WO2010027217A3
公开(公告)日：2010-06-24
申请号：PCT/KR2009005018
申请日：2009-09-04
申请人： DAEWOONG CO LTD , HONG JOON PIO , KWON OH BYUNG , KIM WON CHUL , LIM SEON MOOK , PARK MIN SUN
发明人： HONG JOON PIO , KWON OH BYUNG , KIM WON CHUL , LIM SEON MOOK , PARK MIN SUN
IPC分类号： A61K8/14
CPC分类号： A61K8/553 , A61K8/14 , A61K9/0014 , A61K9/127 , A61Q7/00
摘要： The present invention relates to a topically applicable composition for preventing or treating alopecia caused by a chemotherapeutic agent, including a nanoliposome consisting of a liposome layer containing a lecithin, wherein the nanoliposome includes an epidermal growth factor. In addition, the present invention relates to a pharmaceutical combination which contains the above-described composition and chemotherapeutic agent such that the composition and the chemotherapeutic agent can be individually administered.

10. 发明申请

WO2008066322A1 A STABLE HSA-FREE AND ANTIOXIDANT-FREE PHARMACEUTICAL COMPOSITION COMPRISING INTERFERON-BETA 审中-公开
标题翻译：稳定的无HSA和无抗氧化剂的药物组合物，包含干扰素
公开(公告)号：WO2008066322A1
公开(公告)日：2008-06-05
申请号：PCT/KR2007/006053
申请日：2007-11-28
申请人： DAEWOONG CO., LTD. , KIM, Sun-Hee , LEE, Sang-Kil , AHN, Hyea-Kyung , CHOI, One
发明人： KIM, Sun-Hee , LEE, Sang-Kil , AHN, Hyea-Kyung , CHOI, One
IPC分类号： A61K38/21
CPC分类号： A61K38/215 , A61K9/0019 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , A61K47/32
摘要： Provided is a stable HSA-free and antioxidant-free pharmaceutical composition including: interferon-beta; a buffer with a pH between 3 and 5 including lactic acid or L-histidine; a polyoxyethylene-polyoxypropylene copolymer or polyvinylpyrrolidone; and an isotonic agent. The stable HSA-free pharmaceutical composition prevents the formation of deaminated products or aggregates caused by physical and/or chemical stress, maintains biological activity, and significantly blocks the formation of impurities such as deaminated products, aggregates and oxides of interferon-beta without using an antioxidant such as ethylene-diamine-tetra-acetic acid (EDTA), methionine, or the like.
摘要翻译：提供了稳定的无HSA和抗氧化剂的药物组合物，其包括：干扰素-β; pH为3〜5的缓冲液，包括乳酸或L-组氨酸; 聚氧乙烯 - 聚氧丙烯共聚物或聚乙烯吡咯烷酮; 和等渗剂。稳定的不含HSA的药物组合物防止由物理和/或化学应力引起的脱氨基产物或聚集体的形成，保持生物活性，并且显着阻断杂质的形成，例如脱氨基产物，聚集体和干扰素-β的氧化物，而不使用抗氧化剂如乙二胺四乙酸（EDTA），甲硫氨酸等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式